^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-12 inhibitor

    Related drugs:
    1d
    Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins. (PubMed, Bioorg Chem)
    Immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide degrade IKZF1/3 and are combined with other therapies to treat hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma. Molecular docking studies suggested that DIX-01 may form stable ternary complexes with CRBN-IKZF1 and CRBN-GSPT1, providing a structural basis for its dual-target degradation activity. Furthermore, DIX-01 significantly inhibited tumor growth in a zebrafish xenograft model transplanted with human acute myeloid leukemia cells (MV4-11), supporting its potential as a therapeutic agent for hematologic malignancies.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • GSPT1 (G1 To S Phase Transition 1)
    |
    lenalidomide • pomalidomide
    1d
    RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. (PubMed, Cancer Biol Ther)
    Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)
    |
    lenalidomide • bortezomib • cyclophosphamide
    10d
    Lenalidomide for Adult Histiocyte Disorders (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Feb 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    lenalidomide
    15d
    Updates in low/intermediate-risk MDS. (PubMed, Hematology Am Soc Hematol Educ Program)
    New therapeutic options to reduce the red blood cell (RBC) transfusion burden have emerged since 2020 and include luspatercept and imetelstat. Erythropoiesis-stimulating agents and lenalidomide also address anemia and are generally recommended to start at the time of transfusion dependency, although emerging data suggest that an earlier start of these interventions might offer clinical benefits...Targeted therapy directed to the presence of an IDH1 mutation is U.S. Food and Drug Administration (FDA) approved for the rare IDH1 mutated MDS (<10% of the time) and consideration to use an IDH2 inhibitor for IDH2 mutated MDS (<5% of the time) is reasonable. Interestingly, IDH mutations seem to appear with increased frequency in older patients and in patients with underlying autoimmune/rheumatological disorders.1.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH2 mutation
    |
    lenalidomide • Reblozyl (luspatercept-aamt) • Rytelo (imetelstat)
    16d
    Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome. (PubMed, Front Immunol)
    After induction therapy with the lenalidomide-dexamethasone (RD) regimen, ASCT is performed and partial remission is achieved. The pathogenesis of secondary MDS in POEMS syndrome is discussed from three aspects: cytotoxic therapy, genetic predisposition, and SARS-CoV-2 infection. This case underscores the importance of prolonged surveillance for secondary myeloid neoplasms (sMN) in POEMS patients and suggests that early genomic profiling and individualized treatment may improve outcomes.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • dexamethasone
    17d
    PROTAC-based nanoantigens promote cross-presentation and trafficking of dendritic cell vaccine for enhanced antitumor efficacy. (PubMed, J Immunother Cancer)
    Together, we established a proof of concept for PROTAC in the DC vaccine design by linking E3 ligase to a protein model antigen, which can be readily replaced with other identified pathogenic antigens to elicit robust cytotoxic immune responses against tumors or viral diseases, and thus has serious implications in the clinics.
    Journal
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    lenalidomide
    20d
    Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database. (PubMed, Clin Lymphoma Myeloma Leuk)
    While novel agents continue to expand treatment options, ASCT2 remains a viable therapeutic strategy in appropriately selected patients, especially those with durable responses to prior therapy.
    Clinical • Journal • HEOR • Real-world evidence
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    |
    lenalidomide
    23d
    Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma. (PubMed, Cancer Sci)
    We previously reported that a high Kyn/Trp ratio was associated with poor prognosis in lenalidomide-treated refractory/relapsed MM patients and that IDO expression in stromal cells was upregulated by co-culture with MM cells...These results suggest that the JAK-STAT1-NF-κB-IRF1 signaling pathway may be involved in IDO upregulation. JAK inhibitors may improve the TME in MM and positively influence immunotherapy outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDO1 (Indoleamine 2,3-dioxygenase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    lenalidomide
    23d
    Endothelial cells sense temozolomide resistance to facilitate monocyte-derived macrophage infiltration in glioblastoma. (PubMed, Drug Resist Updat)
    This study identifies a novel signaling cascade whereby TMZ-resistant GBM secretes COL6A1 to activate an IKZF1-UBD axis in ECs, disrupting blood vessel integrity and facilitating MDM infiltration. Our findings delineate the pivotal mechanism by which tumor cells engage ECs to drive MDM infiltration - a linchpin part of the positive-feedback loop that couples TMZ resistance to MDM influx. Targeting IKZF1 with LEN represents a promising strategy for restoring endothelial barrier function, reducing MDM infiltration, and enhancing chemosensitivity in GBM.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • COL6A1 (Collagen Type VI Alpha 1 Chain) • CLDN5 (Claudin 5) • ITGB1 (Integrin Subunit Beta 1)
    |
    lenalidomide • temozolomide
    1m
    NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients. (PubMed, Leuk Lymphoma)
    We report on a series of three patients diagnosed with secondary acute lymphoblastic leukemia (sALL) following treatment for multiple myeloma (MM) where serial, commercially available, next-generation sequencing (NGS) based tracking of measurable residual disease (MRD) using the clonoSEQ assay provided valuable clinical insight. Each of the patients in this series had been treated for their MM with regimens that had included autologous stem cell transplantation following high dose melphalan chemotherapy and had been on maintenance treatment with the immunomodulatory drug lenalidomide for at least one year.
    Journal • Next-generation sequencing
    |
    clonoSEQ
    |
    lenalidomide • melphalan
    1m
    A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis. (PubMed, Blood Adv)
    In conclusion, encouraging activity was seen with blinatumomab and lenalidomide in heavily pre-treated R/R B-NHL. NCI Protocol # 9924.
    P1 data • Journal
    |
    ITGAM (Integrin, alpha M)
    |
    lenalidomide • Blincyto (blinatumomab)